相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer A Phase 2 Nonrandomized Clinical Trial
Emese Zsiros et al.
JAMA ONCOLOGY (2021)
Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients
Jieqiong Liu et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Eric P. Winer et al.
LANCET ONCOLOGY (2021)
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
Sara M. Tolaney et al.
CLINICAL CANCER RESEARCH (2021)
Integrated Profiling Identifies PLOD3 as a Potential Prognostic and Immunotherapy Relevant Biomarker in Colorectal Cancer
Junhong Shi et al.
FRONTIERS IN IMMUNOLOGY (2021)
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The tumor microenvironment (TME) and atezolizumab plus nab-paclitaxel (A plus nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130.
Leisha A. Emens et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA
Anjie Zhu et al.
CANCER BIOLOGY & MEDICINE (2021)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade
Qian Li et al.
CLINICAL CANCER RESEARCH (2020)
B cells are associated with survival and immunotherapy response in sarcoma
Florent Petitprez et al.
NATURE (2020)
B cells and tertiary lymphoid structures promote immunotherapy response
Beth A. Helmink et al.
NATURE (2020)
B cells and TLSs facilitate a response to ICI
Diana Romero
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Breast Cancer, Version 3.2020
William J. Gradishar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
Jieqiong Liu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group
Mohamed Amgad et al.
NPJ BREAST CANCER (2020)
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
iProX: an integrated proteome resource
Jie Ma et al.
NUCLEIC ACIDS RESEARCH (2019)
Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer
Yi Xiao et al.
CLINICAL CANCER RESEARCH (2019)
Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial
Peng Yuan et al.
EUROPEAN JOURNAL OF CANCER (2019)
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
V. Ellen Maher et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review
Claire H. Li et al.
BREAST CANCER RESEARCH (2019)
IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab plus nab-paclitaxel in patients with treatment-naive, locally advanced or metastatic triple-negative breast cancer
L. A. Emens et al.
CANCER RESEARCH (2019)
PLOD3 promotes lung metastasis via regulation of STAT3
Jeong-Hwa Baek et al.
CELL DEATH & DISEASE (2018)
Ubiquitination of tumor suppressor PML regulates prometastatic and immunosuppressive tumor microenvironment
Ya-Ting Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
Martina Schmittnaegel et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy
Sean P. Arlauckas et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models
Ken Ito et al.
CANCER SCIENCE (2017)
Stratification and therapeutic potential of PML in metastatic breast cancer
Natalia Martin-Martin et al.
NATURE COMMUNICATIONS (2016)
A phase II trial of biweekly vinorelbine and oxaliplatin in second-or third-line metastatic triple-negative breast cancer
Jian Zhang et al.
CANCER BIOLOGY & THERAPY (2015)
Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Peter A. Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario
Marta Bonotto et al.
ONCOLOGIST (2014)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortes et al.
LANCET (2011)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer
D. Laessig et al.
ONCOLOGY (2007)
分享论文
